UCL Division of Medicine



The Centre for Radiopharmaceutical Chemistry is a multidisciplinary research centre for the development and clinical translation of novel biomedical imaging agents. We help to tackle the major health challenges of our society by providing new imaging solutions. Embedded within the Departments of Chemistry and Imaging, we work at the interface of chemistry and medicine to provide the next generation of diagnostic agents.

Our work


The lack of radiochemical methods to introduce radioactive labels into small molecules and large macromolecules alike limits the pharmacological space that is accessible with nuclear imaging. We develop new chemical platform techniques that give access to an unprecedented radiochemical space and allow flexible radiotracer design and manufacture in clinical routines.

Sulfonium salt chemistry for aromatic labelling with fluorine-18

Sulfonium salts allow direct labelling of small drug-like molecules with fluorine-18. The appeal of this approach is the ability to label a broad range of bioactive molecules under conditions that mirror conventional substitution reactions with fluoride-18. 

To overcome the synthetic limitations associated with sulfonium salt formation, we developed a novel intramolecular ring-closing reaction that gives access to highly functionalized dibenzothiophene sulfonium salts. The strategy provides a flexible platform and facilitates the development of novel radiotracers for imaging with positron emission tomography.

Radipharmaceutical research figure

Iodine click chemistry for multimodality imaging probes

The ability to study biological processes across cellular and macroscopic scales remains a fundamental goal for molecular imaging. However, no imaging modality meets the need for high resolution, high sensitivity, and deep tissue penetration. With the aim to address this need, we developed a new approach to multiscale multimodal imaging based on a one‐pot synthesis of dual optical and nuclear labelling reagents and applied it to the dual labelling of an antibody.

Radiopharmatheutical research figure

Translational Imaging

Translation of novel radiotracers in clinical studies requires an in-depth understanding of the compound's binding profile at a molecular level. To accelerate clinical applications of radiotracers, we use a translational imaging platform, combining nuclear tissue imaging techniques with in vivo positron emission tomography (PET) and single photon emission computed tomography (SPECT), to assess the suitability of radiotracers for a sought clinical purpose.

Tau PET tracers for imaging of the dementias

Imaging of the microtubule-associated protein tau can potentially provide a surrogate outcome measure for clinical trials, and aid in early, as well as differential, diagnosis of dementias. However, the interpretation of clinical PET scans is challenging. With the aim to understand tracer binding at a molecular level, we assessed the binding profiles of tau tracers in human post-mortem brain tissue.

YouTube Widget Placeholderhttps://www.youtube.com/watch?v=Wcizxk21K54

Imaging of multiple drug resistance

Multiple drug resistance (MDR) is a major clinical challenge for the successful treatment of many prevalent diseases of the central nervous system as well as cancers. In order to evaluate the role of the efflux transporters in the development of MDR and moreover, to provide diagnostic tools to quantify efflux pump activity in vivo, prodrug tracers for dynamic imaging with PET have been developed.

Clinical studies

We provide bespoke imaging agents for clinical research carried out at UCL, UCL Hospitals and partner institutions, and radiotracers developed in-house at the CRC into first in human studies.

Image-Derived Enzymatic Adrenal Lateralisation (IDEAL)

Hypertension is a leading cause of premature morbidity and death globally. Although lifestyle changes and medication can be effective, elevated blood pressure due to secondary disease is difficult to control. This is particularly the case for primary hyperaldosteronism (PHA), which is characterized by excessive aldosterone production by the adrenal gland/s. PHA occurs in 5–10% of patients with hypertension and in 15–25% of those with treatment-resistant hypertension. Although PHA is recognized to be the most common, potentially curable cause of secondary hypertension, only a few patients receive appropriate treatment and care as there are no practical methods to identify those who are likely to benefit from curative surgery.

We have developed AldoView, a new radiotracer labelled with fluorine-18, for imaging with positron emission tomography (PET). In preclinical studies in mice, AldoView showed a favourable pharmacokinetic profile. The tracer was found to demarcate areas with high aldosterone synthase expression levels in human adrenal tissue with high specificity.

With the aim to evaluate the potential of AldoView for non-invasive, image-derived enzymatic lateralization of aldosterone production by the adrenal gland/s with PET, first in human imaging studies will commence in the close future.

Our experts 

Erik Arstad profile

Prof. Erik Årstad

Sander profile

Dr Kerstin Sander

Awais profile

Dr Ramla O. Awais

Dr Sirindil profile

Dr Fatih Sirindil

Glaser profile

Dr Matthias Glaser

Twyman profile

Frazer Twyman

Maher profile

Sinead Maher

Pritchard profile

Dr Dylan Pritchard

Research Fellows 
  • Blanca Szulc 
  • Steven Yap
  • Agostinho Lemos 
  • Thibault Gendron 
  • Raul Pereira 
  • Chris Blunt 
  • Laure Benhamou 
  • Eva Galante 
  • Ran Yan 
  • Carlos Perez-Medina
PhD students
  • Melissa Wren 
  • Brian Pak Kwan Sin 
  • Klaudia Cybulska 
  • Elena Yiannaki 
  • Niral Patel
    • Camila Marcolan

    Selected Publications 

    1. Moscoso A, Wren MC, Arstad E, et al. (2022). Imaging tau pathology in Alzheimer's disease with positron emission tomography: lessons learned from imaging-neuropathology validation studies. Molecular Neurodegeneration, 17 (1). 
    2. Sirindil F, Maher S, Sander K, Årstad E, et al. (2022). Oxidation-Cyclisation of Biphenyl Thioethers to Dibenzothiophenium Salts for Ultrarapid 18F-Labelling of PET Tracers. International Journal of Molecular Sciences, 23 (24).
    3. Sirindil, F., Arstad, E., Sander, K., Awais, R., Twyman, F., Marcolan, C., Glaser, M. (2022). P-161 - Automated production of [(18)^F]AldoView: first translation of a sulfonium salt precursor to GMP.
    4. Yap S,  Arstad E, Sander K, et al. (2021). Ability Of Next-Generation Tau Pet Tracers To Discriminate Alzheimer’s Disease Histopathology From Other Dementias.
    5. Sander K, Gendron T, Arstad E, et al. (2021). Development of [¹⁸F]AldoView as the First Highly Selective Aldosterone Synthase PET Tracer for Imaging of Primary Hyperaldosteronism. Journal of Medicinal Chemistry.
    1. Yap S, Årstad E, Sander K, et al. (2021). Discriminatory ability of next-generation tau PET tracers for Alzheimer's disease. Brain.
    2. Bofinger R, Glaser M, Sander K, et al. (2021). Drug delivery, biodistribution and anti-EGFR activity: theragnostic nanoparticles for simultaneous in vivo delivery of tyrosine kinase inhibitors and kinase activity biosensors. Nanoscale.
    3. Vicente-Rodríguez M, Awais R, Sander K, et al. (2021). Resolving the cellular specificity of TSPO imaging in a rat model of peripherally-induced neuroinflammation. Brain, Behavior, and Immunity. 
    4. Marcolan C, Glaser M, Twyman F, Sander, K, Awais R, Arstad E. (2020). A Generic GC Protocol for the Residual Solvent Analysis of PET Radiopharmaceuticals.
    5. Yap S, Arstad E, Sander K, et al. (2020). High sensitivity of tau radiotracers to depict tau spread in prodromal cases of Alzheimer's disease.
    6. Gendron T, Pereira R, Årstad E, et al. (2020). Iron(II)/Persulfate Mediated Newman-Kwart Rearrangement. Organic Letters.


    Our labs include a radiochemistry research lab and the UCL Good Manufacturing Practice (GMP) Facility in the Kathleen Lonsdale Building, created with generous funding from HEFCE and the UCL Hospitals Biomedical Research Centre. This helps the research and production teams to work towards truly translational research.

    Radiochemistry research lab

    The radiochemistry research lab is designed to allow radiochemistry method development, automated radiotracer production for preclinical studies, and translational nuclear imaging in human specimens. Three shielded fume hoods and two research hot cells equipped with Scintomics synthesis modules are complemented by a dedicated quality control lab.

    UCL GMP Facility

    Custom-designed to produce investigational diagnostic agents for imaging in man, the UCL GMP Facility specialises in the manufacturing of short-lived radiotracers as well as tracers for cutting-edge imaging techniques such as hyperpolarised MRI. The facility houses a class C cleanroom with four Tema hot cells and two class A isolators. Tracer production is carried out on the Trasis AllinOne platform. The dedicated quality control lab features Agilent and Shimadzu high-performance liquid chromatography systems, integrated with Lablogic radio detectors, an Agilent gas chromatography, radio TLC system and Endosafe equipment for pyrogen testing.

    Radiochemistry facilities

    GMP Facility

    Interested in joining us?

    Collaborations are strongly encouraged both within and external to UCL. We provide radiotracers and services for clinical and preclinical projects through the UCL GMP Facility and the research facility, respectively. We constantly implement new tracer products as well as radiochemical methods and imaging techniques. Please do get in touch if you would like to work with us.

    Contact details

    Postal and Visiting Address

    Centre for Radiopharmaceutical Chemistry (CRC)
    Kathleen Lonsdale Building
    5 Gower Place
    London, WC1E 6BS